-

Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2023 financial results on Thursday, May 11th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 11th, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Industry:

Charles River Laboratories International, Inc.

NYSE:CRL
Release Summary
Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
Release Versions
English
$Cashtags
$CRL
Hashtags
#CRL
#CharlesRiver
#CharlesRiverLaboratories
#CharlesRiverLabs

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com...

Charles River Laboratories Announces First-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results...

Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated...
Back to Newsroom